Takeda Pharmaceutical Company Limited (TKDA) — Cash Flow Reinvestment Rate
Takeda Pharmaceutical Company Limited (TKDA) has a Cash Flow Reinvestment Rate of 0.63x as of December 2025, reinvesting €235.74 Billion (capex €222.37 Billion plus investments €-13.37 Billion) from operating cash flow of €373.25 Billion. See Takeda Pharmaceutical Company Limited free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Takeda Pharmaceutical Company Limited Cash Flow Reinvestment Rate (2017–2025)
Historical reinvestment intensity for Takeda Pharmaceutical Company Limited across 9 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Takeda Pharmaceutical Company Limited.
Annual Cash Flow Reinvestment Rate for Takeda Pharmaceutical Company Limited (2017–2025)
Year-by-year capital reinvestment analysis for Takeda Pharmaceutical Company Limited. See TKDA free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.44x | €461.57 Billion | €1.06 Trillion | €379.62 Billion | ▼ -66.9% |
| 2024 | 1.32x | €944.59 Billion | €716.34 Billion | €480.73 Billion | ▲ +3.8% |
| 2023 | 1.27x | €1.24 Trillion | €977.16 Billion | €633.69 Billion | ▲ +981.8% |
| 2022 | 0.12x | €131.83 Billion | €1.12 Trillion | €123.25 Billion | ▼ -31.5% |
| 2021 | 0.17x | €173.21 Billion | €1.01 Trillion | €111.21 Billion | ▼ -32.1% |
| 2020 | 0.25x | €168.93 Billion | €669.75 Billion | €127.08 Billion | ▼ -34.0% |
| 2019 | 0.38x | €125.61 Billion | €328.48 Billion | €77.68 Billion | ▲ +59.0% |
| 2018 | 0.24x | €90.86 Billion | €377.85 Billion | €67.00 Billion | ▼ -8.2% |
| 2017 | 0.26x | €68.50 Billion | €261.36 Billion | €61.66 Billion | — |